<DOC>
	<DOC>NCT02955706</DOC>
	<brief_summary>clinical trial to assess the efficacy of Acetyl-L-carnitine</brief_summary>
	<brief_title>Assessment the Efficacy of Acetyl-L-carnitine in Patient With Alzheimer's Disease</brief_title>
	<detailed_description>A multicenter, randomized, double-blind, placebo-controlled clinical trial to assess the efficacy of Acetyl-L-carnitine in patient with Alzheimer's disease</detailed_description>
	<mesh_term>Alzheimer Disease</mesh_term>
	<mesh_term>Acetylcarnitine</mesh_term>
	<criteria>More than 50 Years probable Alzheimer disease according to DSMIV and NINCDSADRDA standard 12≤KMMSE(screening)≤26 be able to perform examinations Patient taking donepezil(5mg or 10mg/day) more than 3 months be able to visit to hospital with caregiver possible or probable or definite vascular dementia according to NINDSAIREN standard CNS disease(Cerebrovascular diseases, Epilepsy etc) to cause dementia Illiteracy Patient taking galantamine, memantine, rivastigmine within three months Patient taking brain enhancer, thyroid hormone within 4 weeks Patient taking Central nervous system stimulant, Antipsychotic agent, anticholinergic agent within 2 weeks at screenig blood test: AST, ALT≥ 3 X upper limit of normal range or Hb≤8g/dL or platelet&lt;100,000/mm3 or Serum creatinine ≥ 3 X upper limit of normal range Abnormal result of Vit.B12, Syphilis serology, TSH Severe Depression, Schizophrenia, Alcoholism, Drug addiction Parkinson's disease (need to drug therapy) Angina, Myocardial infarction, ischemia within six months Head injury with sense of loss within six months Patient taking other IP within three months Hypersensitivity to IP Sever Hearing problems or Visual impairment</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>